Bischof P, DuBerg S, Sizonenko M T, Schindler A M, Béguin F, Herrmann W L, Sizonenko P C
Am J Obstet Gynecol. 1984 Jan 1;148(1):13-8. doi: 10.1016/s0002-9378(84)80025-3.
Immunohistochemical techniques and direct measurements of pregnancy-associated plasma protein A (PAPP-A) have demonstrated the presence of PAPP-A in trophoblast and decidua. The purpose of the present study was to investigate the possibility that these tissues are capable of producing PAPP-A in vitro. Trophoblast and decidua were obtained from term deliveries and from legal surgical terminations of pregnancy (7 to 12 weeks). In addition to trophoblast and decidua, myometrium was also obtained during two hysterectomies in the first trimester of pregnancy. Tissues were incubated in medium 199 at 37 degrees C under an oxygen/carbon dioxide atmosphere. Media containing either pregnancy-associated serum or non-pregnancy-associated serum were changed after 8 hours of incubation in medium 199 alone. In addition to PAPP-A, human placental lactogen (hPL) and prolactin (Prl) were measured in homogenates and media by radioimmunoassays in order to confirm the viability of the cultured tissues. Addition of pregnancy-associated serum to the media induced a significant release of PAPP-A from trophoblast and decidua when compared to that in control cultures. Non-pregnancy-associated serum had no effect. Myometrium did not release any measurable PAPP-A into the medium even in the presence of pregnancy-associated serum. Cycloheximide added to pregnancy-associated serum significantly inhibited the release of PAPP-A from trophoblast and decidua. These last tissues, irrespective of the culture condition, released significantly more PAPP-A as well as hPL and Prl than was initially present in the tissue. These data demonstrate that PAPP-A is released in vitro by trophoblast and decidua (but not by myometrium) and that this release can be magnified by a factor present only in pregnancy-associated serum. The release of PAPP-A, hPL, and Prl is considered as a de novo production since concentration of these proteins are higher in media and tissues after incubation compared to concentrations initially present in the tissue before culture and since cycloheximide significantly inhibits the release of PAPP-A, Prl, and hPL from the cultured tissues.
免疫组织化学技术和对妊娠相关血浆蛋白A(PAPP-A)的直接测量已证明滋养层和蜕膜中存在PAPP-A。本研究的目的是探讨这些组织在体外产生PAPP-A的可能性。滋养层和蜕膜取自足月分娩以及合法的妊娠中期手术终止妊娠(7至12周)。除了滋养层和蜕膜外,还在妊娠早期的两次子宫切除术中获取了子宫肌层。组织在含199培养基中于37℃、氧气/二氧化碳气氛下孵育。仅在含199培养基中孵育8小时后,更换含有妊娠相关血清或非妊娠相关血清的培养基。为了确认培养组织的活力,通过放射免疫测定法在匀浆和培养基中测量人胎盘催乳素(hPL)和催乳素(Prl)。与对照培养相比,向培养基中添加妊娠相关血清可诱导滋养层和蜕膜显著释放PAPP-A。非妊娠相关血清无此作用。即使存在妊娠相关血清,子宫肌层也不会向培养基中释放任何可测量的PAPP-A。添加到妊娠相关血清中的放线菌酮显著抑制滋养层和蜕膜释放PAPP-A。这些组织,无论培养条件如何,释放的PAPP-A以及hPL和Prl均显著多于组织最初所含的量。这些数据表明,PAPP-A可由滋养层和蜕膜在体外释放(但子宫肌层不能),且这种释放可被仅存在于妊娠相关血清中的一种因子放大。PAPP-A、hPL和Prl的释放被认为是重新合成,因为与培养前组织中最初存在的浓度相比,孵育后培养基和组织中这些蛋白质的浓度更高,且放线菌酮显著抑制培养组织释放PAPP-A、Prl和hPL。